SCHEMBL16811786

SCHEMBL16811786

Cc1ccc(-c2cc(C(=O)NC3CCN(Cc4ccc(N5CCC(C)CC5)nc4)CC3)ccc2C)cn1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMO Q99835 1/20 0.60
▸ MAPK14 Q16539 8/20 0.47
▸ SSTR5 P35346 4/20 0.47
▸ DRD4 P21917 2/20 0.45
▸ HPGDS O60760 2/20 0.45
▸ NPC1 O15118 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ LMNA P02545 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ HDAC6 Q9UBN7 1/20 0.44
▸ ACKR3 P25106 1/20 0.44
▸ MAPK11 Q15759 2/20 0.44
▸ MAPK13 O15264 1/20 0.44
▸ MAPK12 P53778 1/20 0.44
▸ LCK P06239 1/20 0.43
▸ CSF1R P07333 1/20 0.43
▸ KDR P35968 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18286469 0.93 SMO (0.58) SMOMAPK14SSTR5DRD4HPGDS
SCHEMBL16811807 0.93 SMO (0.64) SMOMAPK14DRD4LMNASMN1; SMN2
SCHEMBL16811783 0.92 SMO (0.59) SMOSSTR5DRD4HPGDSNPC1
SCHEMBL16811799 0.92 SMO (0.59) SMOSSTR5DRD4HPGDSNPC1
SCHEMBL16811831 0.91 SMO (0.74) SMOMAPK14SSTR5DRD4NPC1
SCHEMBL16811851 0.91 SMO (0.62) SMOMAPK14SSTR5DRD4HPGDS
SCHEMBL16811800 0.89 SMO (0.56) SMOMAPK14SSTR5DRD4HPGDS
SCHEMBL16812724 0.89 SMO (0.52) SMOMAPK14SSTR5DRD4HPGDS
SCHEMBL18286583 0.88 SMO (0.52) SMOMAPK14SSTR5DRD4HPGDS
SCHEMBL16812011 0.88 SMO (0.81) SMOMAPK14SSTR5DRD4ACKR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150166509-A1 SMOOTHENED MODULATORS AND METHODS OF USE THEREOF UNIV DUKE (US) 2015-06-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150166509-A1 SMOOTHENED MODULATORS AND METHODS OF USE THEREOF SMO, SHH, GLI1 SMO 1/4885MAPK14 1495/4885SSTR5 1894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback